Author + information
- Received September 27, 2004
- Revision received March 3, 2005
- Accepted March 10, 2005
- Published online July 5, 2005.
- William T. Abraham, MD, FACC⁎,⁎ (, )
- Kirkwood F. Adams, MD, FACC†,
- Gregg C. Fonarow, MD, FACC‡,
- Maria Rosa Costanzo, MD, FACC§,
- Robert L. Berkowitz, MD, FACC∥,
- Thierry H. LeJemtel, MD¶,
- Mei L. Cheng, PhD#,
- Janet Wynne, MS#,
- ADHERE Scientific Advisory Committee and Investigators,
- ADHERE Study Group
- ↵⁎Reprint requests and correspondence:
Dr. William T. Abraham, 473 West 12th Avenue, Suite 110P, Davis Heart and Lung Research Institute, Columbus, Ohio 43210-1252.
Objectives We sought to compare the in-hospital mortality of patients with acute decompensated heart failure (ADHF) who were receiving parenteral treatment with one of four intravenous vasoactive medications.
Background There are limited data regarding the effects of the choice of intravenous vasoactive medication on in-hospital mortality in patients hospitalized with ADHF.
Methods This was a retrospective analysis of observational patient data from the Acute Decompensated Heart Failure National Registry (ADHERE), a multicenter registry designed to prospectively collect data on each episode of hospitalization for ADHF and its clinical outcomes. Data from the first 65,180 patient episodes (October 2001 to July 2003) were included in this analysis. Cases in which patients received nitroglycerin, nesiritide, milrinone, or dobutamine were identified and reviewed (n = 15,230). Risk factor and propensity score-adjusted odds ratios (ORs) for in-hospital mortality were calculated.
Results Patients who received intravenous nitroglycerin or nesiritide had lower in-hospital mortality than those treated with dobutamine or milrinone. The risk factor and propensity score-adjusted ORs for nitroglycerin were 0.69 (95% confidence interval [CI] 0.53 to 0.89, p ≤ 0.005) and 0.46 (94% CI 0.37 to 0.57, p ≤ 0.005) compared with milrinone and dobutamine, respectively. The corresponding values for nesiritide compared with milrinone and dobutamine were 0.59 (95% CI 0.48 to 0.73, p ≤ 0.005) and 0.47 (95% CI 0.39 to 0.56, p ≤ 0.005), respectively. The adjusted OR for nesiritide compared with nitroglycerin was 0.94 (95% CI 0.77 to 1.16, p = 0.58).
Conclusions Therapy with either a natriuretic peptide or vasodilator was associated with significantly lower in-hospital mortality than positive inotropic therapy in patients hospitalized with ADHF. The risk of in-hospital mortality was similar for nesiritide and nitroglycerin.
This study was funded by Scios, Inc. Dr. Adams is a consultant for and receives research support from Scios Inc.; Drs. Berkowitz, Costanzo, and Abraham are consultants for Scios Inc.; and Dr. Fonarow is a consultant for Scios Inc. and Biosite.
- Received September 27, 2004.
- Revision received March 3, 2005.
- Accepted March 10, 2005.
- American College of Cardiology Foundation